EN
$176.00
+2.95
(+1.70%)
As of Oct 20, 2026, 5:48 PM EDT
Price history
Ensign Group Inc (ENSG) is trading up at $176.00 (+1.70%), as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.
Ensign Group Inc revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.65B | $1.85B | $1.75B | $2.04B | $2.40B | $2.63B | $3.03B | $3.73B | $4.26B | $5.06B |
| Growth (year over year) | +23.3% | +11.8% | −5.1% | +16.1% | +18.0% | +9.4% | +15.1% | +23.3% | +14.2% | +18.7% |
| Gross profit | $313.1M | $535.9M | $336.4M | $415.9M | $537.4M | $607.6M | $671.0M | $788.1M | $883.6M | $1.04B |
| Gross margin | 18.9% | 29.0% | 19.2% | 20.4% | 22.4% | 23.1% | 22.2% | 21.1% | 20.7% | 20.5% |
| Operating income | $91.8M | $43.2M | $84.9M | $129.2M | $223.2M | $260.5M | $296.8M | $255.4M | $358.3M | $425.3M |
| Operating margin | 5.6% | 2.3% | 4.8% | 6.3% | 9.3% | 9.9% | 9.8% | 6.8% | 8.4% | 8.4% |
| Net income | $50.0M | $40.5M | $92.4M | $110.5M | $170.5M | $194.7M | $224.7M | $209.4M | $298.0M | $344.0M |
| Net margin | 3.0% | 2.2% | 5.3% | 5.4% | 7.1% | 7.4% | 7.4% | 5.6% | 7.0% | 6.8% |
| EPS (diluted) | $0.96 | $0.77 | $1.70 | $1.97 | $3.06 | $3.42 | $3.95 | $3.65 | $5.12 | $5.84 |
| Balance sheet | ||||||||||
| Cash and equivalents | $57.7M | $42.3M | $31.0M | $59.2M | $236.6M | $262.2M | $316.3M | $509.6M | $464.6M | $503.9M |
| Total assets | $1.00B | $1.10B | $2.20B | $2.36B | $2.55B | $2.85B | $3.45B | $4.18B | $4.67B | $5.46B |
| Total liabilities | $540.5M | $602.4M | $1.59B | $1.71B | $1.73B | $1.83B | $2.20B | $2.68B | $2.83B | $3.23B |
| Long-term debt | $275.5M | $303.0M | $233.1M | $330.4M | $117.6M | $152.9M | $149.3M | $145.5M | $141.6M | $137.5M |
| Shareholders' equity | $456.4M | $492.4M | $590.9M | $654.2M | $818.1M | $1.02B | $1.25B | $1.49B | $1.84B | $2.23B |
| Cash flow | ||||||||||
| Operating cash flow | $73.9M | $79.5M | $210.3M | $192.2M | $373.4M | $275.7M | $272.5M | $376.7M | $347.2M | $564.3M |
| Capital expenditure | $65.7M | $54.1M | $50.9M | $71.5M | — | — | — | — | — | — |
| Free cash flow | $8.19M | $25.5M | $159.4M | $120.7M | — | — | — | — | — | — |
| Dividends paid | $8.17M | $8.72M | $9.42M | $10.2M | $10.8M | $11.5M | $12.2M | $12.9M | $13.7M | $14.4M |
| Share buybacks | $30.0M | $7.29M | $0 | $6.41M | $25.0M | $10.1M | $29.9M | $0 | $0 | $20.0M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.08B | $1.13B | $1.17B | $1.23B | $1.30B | $1.36B | $1.39B | $1.44B |
| Growth (year over year) | +15.0% | +15.5% | +16.1% | +18.5% | +19.8% | +20.2% | +18.4% | +17.3% |
| Gross profit | $221.8M | $235.0M | $245.2M | $256.0M | $251.7M | $285.8M | $293.4M | $306.2M |
| Gross margin | 20.5% | 20.8% | 20.9% | 20.8% | 19.4% | 21.0% | 21.1% | 21.3% |
| Operating income | $89.3M | $100.8M | $101.4M | $103.9M | $96.2M | $123.8M | $124.9M | $122.5M |
| Operating margin | 8.3% | 8.9% | 8.6% | 8.5% | 7.4% | 9.1% | 9.0% | 8.5% |
| Net income | $78.4M | $79.7M | $80.3M | $84.4M | $83.8M | $95.5M | $99.7M | $99.7M |
| Net margin | 7.3% | 7.0% | 6.8% | 6.9% | 6.5% | 7.0% | 7.2% | 6.9% |
| EPS (diluted) | $1.34 | $1.37 | $1.37 | $1.44 | $1.42 | $1.61 | $1.67 | $1.68 |
| Balance sheet | ||||||||
| Cash and equivalents | $532.1M | $464.6M | $282.7M | $364.0M | $443.7M | $503.9M | $539.5M | $262.3M |
| Total assets | $4.63B | $4.67B | $4.76B | $4.93B | $5.23B | $5.46B | $5.61B | $5.75B |
| Total liabilities | $2.88B | $2.83B | $2.83B | $2.91B | $3.10B | $3.23B | $3.24B | $3.30B |
| Long-term debt | $142.6M | $141.6M | $140.6M | $139.6M | $138.6M | $137.5M | $136.5M | $135.6M |
| Shareholders' equity | $1.75B | $1.84B | $1.93B | $2.02B | $2.12B | $2.23B | $2.37B | $2.44B |
| Cash flow | ||||||||
| Operating cash flow | $134.5M | $100.5M | $72.2M | $155.7M | $153.0M | $183.3M | $100.2M | $172.0M |
| Dividends paid | $3.42M | $3.44M | $3.59M | $3.60M | $3.60M | $3.62M | $3.77M | $3.80M |
| Share buybacks | $0 | $0 | $10.8M | $9.22M | $0 | $0 | $0 | $40.0M |
From Ensign Group Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Ensign Group Inc
- Headquarters
- San Juan Capistrano, California From SEC filings, Oct 2026
Recent News (14)
-
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in The Ensign Group, Inc. (NASDAQ: ENSG) to Contact Law Firm The Ensign Group, Inc. (NASDAQ: ENSG) shareholders should email fletcher@fmoorelaw.com NEW YORK, Oct. 20, 2026 /PRNewswire/ -- What Happened? Ensign is a healthcare services company that operates skil…
-
Mark Parkinson, Ensign Group director, sells $17,962 in shares
Mark Parkinson, Ensign Group director, sells $17,962 in shares
-
Ensign Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Ensign Group, Inc. - ENSG NEW ORLEANS, Oct. 16, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 7, 2026 to file lead plaintiff applications in a securit…
-
The Ensign Group, Inc. (ENSG) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Oct. 15, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to The Ensign Group, Inc. (ENSG) have opportunity to lead the securities fraud …
-
-
-
ENSG Investors Have Opportunity to Lead The Ensign Group, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm NEW YORK, Oct. 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of The Ensign Group,…
-
-
ENSG Stock Alert: Ensign Group Neglect Issues and Subsequent 8% Stock Drop Trigger Securities Fraud Class Action for Investors Ensign has been sued for securities fraud after its stock price fell following reports alleging that the company concealed patient neglect, understaffing, manipulated quality and staffing data, improp…
-
-
-
-
-
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International